Premium
Comparable outcomes in chronic lymphocytic leukaemia ( CLL ) patients treated with reduced‐dose ibrutinib: results from a multi‐centre study
Author(s) -
Mato Anthony R.,
Timlin Colleen,
Ujjani Chaitra,
Skarbnik Alan,
Howlett Christina,
Banerjee Rahul,
Nabhan Chadi,
Schuster Stephen J.
Publication year - 2018
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.14540
Subject(s) - ibrutinib , medicine , bruton's tyrosine kinase , dosing , progression free survival , chronic lymphocytic leukemia , oncology , pharmacology , leukemia , tyrosine kinase , chemotherapy , receptor